Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.89 and traded as low as $1.50. Nabriva Therapeutics shares last traded at $1.51, with a volume of 19,485 shares trading hands.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on NBRV. Northland Securities lowered shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research report on Friday, January 6th. StockNews.com started coverage on Nabriva Therapeutics in a report on Wednesday. They set a "hold" rating on the stock.
Get Nabriva Therapeutics alerts:Nabriva Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 1.40. The firm has a fifty day simple moving average of $1.89 and a 200 day simple moving average of $3.61. The company has a market cap of $46.26 million, a price-to-earnings ratio of -0.08 and a beta of 1.67.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) EPS for the quarter, missing the consensus estimate of ($4.03) by ($0.18). Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. The company had revenue of $9.15 million for the quarter, compared to analyst estimates of $10.68 million. On average, sell-side analysts expect that Nabriva Therapeutics plc will post -17.37 earnings per share for the current fiscal year.Hedge Funds Weigh In On Nabriva Therapeutics
A hedge fund recently raised its stake in Nabriva Therapeutics stock. Renaissance Technologies LLC lifted its stake in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.23% of the company's stock.
About Nabriva Therapeutics
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Featured Articles
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.